<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01683747</url>
  </required_header>
  <id_info>
    <org_study_id>110376</org_study_id>
    <nct_id>NCT01683747</nct_id>
  </id_info>
  <brief_title>Single Dose Enteral Tranexamic Acid in Critically Ill Patients</brief_title>
  <official_title>Single Dose Enteral Tranexamic Acid for the Reduction of Morbidity in Hospitalized Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Diego Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inflammagen/Leading Ventures</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Diego Veterans Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The premise of this study is that enteral tranexamic acid will help to maintain small bowel&#xD;
      integrity, which is often compromised by critical illness due to inadequate cardiovascular&#xD;
      perfusion (i.e., shock), and that maintenance of small bowel integrity will decrease&#xD;
      morbidity in critically ill patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to provide preliminary efficacy and safety data on the&#xD;
      enteral administration of a one-time dose of tranexamic acid to critically ill patients for&#xD;
      the reduction of morbidity at 28 days after enrollment in the study.&#xD;
&#xD;
      Secondary objectives of this study are to determine the efficacy of administration of enteral&#xD;
      tranexamic acid in reducing intensive care unit (ICU) and hospital length-of-stay, as well&#xD;
      and mortality and morbidity at 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lower than anticipated enrollment&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>28 days</time_frame>
    <description>Morbidity will be assessed at 28 days as measured by the validated Self-Administered Quality of Well-being Scale (QWB-SA) and 5-Point modified Oxford Handicap Scale [secondary scale]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>6 months</time_frame>
    <description>Morbidity will be assessed at 28 days as measured by the validated Self-Administered Quality of Well-being Scale (QWB-SA) and 5-Point modified Oxford Handicap Scale [secondary scale]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause death will be measured at 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months</time_frame>
    <description>All cause mortality will be measured at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time spent as a patient in the ICU will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time spent in the hospital as a patient will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Shock</condition>
  <condition>Sepsis</condition>
  <condition>Hypotension</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study group receives enteral tranexamic acid in normal saline in addition to usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group receives vehicle (normal saline) without study drug and usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Cyclokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Intervention (Carrier fluid only)</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critically ill patients admitted to ICU within 48 hours of onset of illness&#xD;
&#xD;
          -  Patients with feeding tubes (e.g., orogastric, nasogastric, PEG, etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary admitting diagnosis of cancer&#xD;
&#xD;
          -  primary admitting diagnosis of acute congestive heart failure&#xD;
&#xD;
          -  primary admitting diagnosis of chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  primary admitting diagnosis of acute myocardial infarction or unstable cardiac&#xD;
             arrythmia&#xD;
&#xD;
          -  primary admitting diagnosis of amyotrophic lateral sclerosis (ALS) or other&#xD;
             non-infectious disease&#xD;
&#xD;
          -  primary admitting diagnosis of post-operative neurosurgical procedure&#xD;
&#xD;
          -  known hypersensitivity to tranexamic acid&#xD;
&#xD;
          -  acquired disturbances of color vision&#xD;
&#xD;
          -  hematuria cause by disease of the renal parenchyma&#xD;
&#xD;
          -  active thromboembolic disease such as deep venous thrombosis or pulmonary embolism&#xD;
&#xD;
          -  patients with known clotting disorders or other known bleeding disorders&#xD;
&#xD;
          -  recent (within 3 months) or active cerebrovascular bleed&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  inability to take study medicine (i.e., ileus with &gt; 500ml stomach residuals, NPO&#xD;
             status)&#xD;
&#xD;
          -  patients excluded at the discretion of the treating physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik B Kistler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA San Diego Healthcare/University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Health Care System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>September 9, 2012</study_first_submitted>
  <study_first_submitted_qc>September 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2012</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Diego Veterans Healthcare System</investigator_affiliation>
    <investigator_full_name>Erik B. Kistler, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>shock</keyword>
  <keyword>placebo controlled</keyword>
  <keyword>double blinded</keyword>
  <keyword>interventional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

